Show simple item record

dc.contributor.authorJones, R
dc.contributor.authorCrabb, S
dc.contributor.authorChester, J
dc.contributor.authorElliott, Tony
dc.contributor.authorHuddart, R
dc.contributor.authorBirtle, A
dc.contributor.authorEvans, L
dc.contributor.authorLester, J
dc.contributor.authorJagdev, S
dc.contributor.authorCasbard, A
dc.contributor.authorHuang, C
dc.contributor.authorMadden, TA
dc.contributor.authorGriffiths, G
dc.date.accessioned2020-06-15T12:57:38Z
dc.date.available2020-06-15T12:57:38Z
dc.date.issued2020en
dc.identifier.citationJones R, Crabb S, Chester J, Elliott T, Huddart R, Birtle A, et al. A randomised Phase II trial of carboplatin and gemcitabine +/- vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin. BJU Int. 2020.en
dc.identifier.pmid32336008en
dc.identifier.doi10.1111/bju.15096en
dc.identifier.urihttp://hdl.handle.net/10541/622972
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/ 10.1111/bju.15096en
dc.titleA randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer patients not suitable to receive cisplatinen
dc.typeArticleen
dc.contributor.departmentUniversity of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.en
dc.identifier.journalBJU Internationalen
dc.description.noteen]
refterms.dateFOA2020-06-19T13:10:57Z


Files in this item

Thumbnail
Name:
BJUI Crabb.pdf
Size:
310.9Kb
Format:
PDF
Description:
Open Access

This item appears in the following Collection(s)

Show simple item record